Intensive care medicine

Medicine

Journal of Hepatology

There is currently robust discussion regarding the newly proposed metabolic dysfunction-associated fatty liver disease (MAFLD) definition.1 As compared to its predecessor – non-alcoholic fatty liver disease (NAFLD), MAFLD is a diagnosis of inclusion relying on a set of metabolic risk factors and the presence of hepatic steatosis.2–5 There is evidence in epidemiology studies of discrepancies between the two definitions.6–8 However, no studies have examined the two definitions in well-defined clinical cohorts.

Clinical utility of the MAFLD definition